Navigation Links
Watson's Nabumetone Tablets Receive FDA Approval
Date:6/17/2011

PARSIPPANY, N.J., June 17, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly.

Nabumetone had total U.S. sales of $58 million for the twelve months ending April 30, 2011, according to IMS Health.  Nabumetone is indicated for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Nabumetone Tablets
2. Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
3. Breckenridge Announces Approval of Letrozole Tablets
4. Mylan Receives Approval for Generic Version of Aricept® Tablets
5. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
6. TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from Chinas SFDA
7. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
8. Mylan Launches Generic Version of Roxicodone® Tablets
9. Qualitest Receives FDA Approval for Dexamethasone Elixir, USP, 0.5mg/ 5 mL and Orsythia™ Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.1 mg/0.02 mg)
10. Shionogi Inc. Announces Publication of Data in Pediatrics Demonstrating Efficacy of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets as Add-On Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
11. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... ... open for the 31st annual AIDS Walk Boston & 5K Run , which will ... event regularly draws thousands of participants, making it AIDS Action Committee’s largest annual fundraiser. The ... USA Track & Field Association. , The AIDS Walk & 5K Run will begin ...
(Date:5/3/2016)... ... May 03, 2016 , ... Cosmetic surgeon Dr. Mark Youssef first ... incorporating the injectable filler into his menu of services to give his patients as ... a year later, he’s still improving his approach to ensure he stays at the ...
(Date:5/3/2016)... ... May 03, 2016 , ... University of the People, the ... of its Associates and Bachelor's degrees in Health Studies. Leading figures are heading ... Torsten N. Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, Stanley ...
(Date:5/3/2016)... ... , ... Nationally recognized personal injury law firm Monge & Associates is honoring Moms ... who wants one for their Mother or any other mother figure. , According to law ... Monge goes on to say, “we are choosing to do this by giving free ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):